Pepper Ruth J, Gale Daniel P, Wajed Julekha, Bommayya Girish, Ashby Damien, McLean Adam, Laffan Mike, Maxwell Patrick H
Department of Renal Medicine, West London Renal and Transplant Centre, Hammersmith Hospital, London, UK.
Hemodial Int. 2007 Oct;11(4):430-4. doi: 10.1111/j.1542-4758.2007.00213.x.
Large-bore dual lumen in-dwelling venous catheters are used in hemodialysis. These catheters are usually locked with heparin after the treatment. This study addressed the underappreciated postdialysis coagulopathy that can result. Thirty-six patients were included: 7 dialyzed through arterio-venous fistulae, 29 through in-dwelling venous catheters. The latter group was further subdivided according to whether they received heparin or heparin-free dialysis. To assess the heparin lock, a full-dose heparin lock as well as a much weaker heparin lock and a citrate lock were used. To assess the coagulopathy, blood was taken 1 hr after dialysis. The activated partial thromboplastin time (APTT) and anti-Xa level was measured. Additionally, 6 venous catheters were removed and the amount of fluid expelled upon locking with saline was measured. Clotting from the patient group with arterio-venous fistulae was normal following dialysis. The patients with in-dwelling venous catheters and heparin locks had significantly deranged clotting; 6 out of 10 patients had abnormal APTT results. All patients with catheters, heparin-free dialysis, and heparin locks had deranged clotting (7 out of 7). The rate decreased significantly when heparinized saline was used as a lock. A subset of patients had a citrate lock rather than a heparin lock; the clotting results normalized in all but one patient. An in vitro study demonstrated immediate leakage of fluid from the end of the ports upon locking. Significant postdialysis anticoagulation can occur after dialysis, which can be attributed to the heparin line locks. This risk is considerably reduced when a citrate lock is used instead.
大口径双腔留置静脉导管用于血液透析。这些导管通常在治疗后用肝素封管。本研究探讨了可能由此导致的未被充分认识的透析后凝血病。纳入36例患者:7例通过动静脉内瘘进行透析,29例通过留置静脉导管进行透析。后一组根据是否接受肝素或无肝素透析进一步细分。为评估肝素封管效果,使用了全剂量肝素封管以及较弱的肝素封管和枸橼酸盐封管。为评估凝血病,在透析后1小时采血,测量活化部分凝血活酶时间(APTT)和抗Xa水平。此外,取出6根静脉导管,测量用生理盐水封管时排出的液体量。动静脉内瘘患者组透析后凝血正常。留置静脉导管并用肝素封管的患者凝血明显紊乱;10例患者中有6例APTT结果异常。所有使用导管、无肝素透析且用肝素封管的患者凝血均紊乱(7例均如此)。当使用肝素化生理盐水封管时,发生率显著降低。一部分患者使用枸橼酸盐封管而非肝素封管;除1例患者外,所有患者的凝血结果均恢复正常。一项体外研究表明,封管时端口末端会立即出现液体渗漏。透析后可发生显著的抗凝作用,这可归因于肝素封管。改用枸橼酸盐封管时,这种风险会大幅降低。